
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Brookline Capital Markets boosted their Q4 2026 EPS estimates for Candel Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.32). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.22) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.42) EPS.
Several other brokerages have also recently commented on CADL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Jefferies Financial Group began coverage on shares of Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price target on the stock. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Citigroup reduced their target price on shares of Candel Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a report on Monday. Finally, Stifel Nicolaus decreased their price target on Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.29.
Candel Therapeutics Stock Performance
Shares of NASDAQ:CADL opened at $5.32 on Tuesday. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $417.35 million, a P/E ratio of -3.59 and a beta of -0.27. The business has a 50-day moving average price of $9.33 and a two-hundred day moving average price of $8.39. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $14.00.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in CADL. BlackRock Inc. bought a new position in Candel Therapeutics during the second quarter worth about $51,181,000. Portolan Capital Management LLC raised its stake in Candel Therapeutics by 1.4% during the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock worth $36,943,000 after acquiring an additional 48,163 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Candel Therapeutics by 4.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock valued at $3,316,000 after purchasing an additional 12,385 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Candel Therapeutics in the 2nd quarter valued at $2,873,000. Finally, Wellington Management Group LLP bought a new position in Candel Therapeutics in the second quarter valued at about $2,119,000. Institutional investors own 13.93% of the company’s stock.
More Candel Therapeutics News
Here’s some of the latest news about CADL:
- Positive Sentiment: Zacks Research upgraded CADL from “strong sell” to “hold,” suggesting a less bearish view, though the new rating is not a buy recommendation. Zacks Research ratings
- Positive Sentiment: HC Wainwright reiterated a “Buy” rating and an $18 price target, and raised its FY2026 loss forecast to a narrower $1.19 per share from $1.28. However, it also reduced several later-year earnings estimates. Analyst estimates and rating
- Negative Sentiment: Despite its Buy rating, HC Wainwright lowered projected earnings for FY2027–FY2030, including cutting FY2029 EPS from $1.41 to $0.60 and FY2030 EPS from $2.07 to $1.31. The revisions temper the longer-term bullish outlook. HC Wainwright earnings estimates
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
